FindTrial
Sign In

To check the safety of 3 test product for skin irritation

Evaluation of skin safety of 3 test products for Primary Skin Irritation Using Skin Irritation Test (Patch Test in Humans). IS 4011:2018 Guidelines.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/04/033202
Enrollment
60
Registered
2021-04-28
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: AB Next Gel: 0.04 gm of test product will be filled in wells of the patch chambers. Then it will be occluded. Duration of occlusion will be 24 hours. Control Intervention1: Epiduo Gel:

Sponsors

Lupin Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Fitzpatrick skin type III to IV. Having apparently healthy skin on test area. Willingness to avoid intense UV exposure on test site (sun or artificial UV), during the course of the study.

Exclusion criteria

Exclusion criteria: Pregnancy (by history) and lactating women. Scars, excessive terminal hair or tattoo on the studied area. Hypersensitivity, allergy antecedent (to any cosmetic product, raw material, hair dye)

Design outcomes

Primary

MeasureTime frame
Evaluation of cutaneous tolerance by dermatological scoring of skin reactions using Draize scale. Evaluation of erythema using spectrophotometer (a value)Timepoint: 48 hours—

Secondary

MeasureTime frame
NoneTimepoint: None—

Countries

India

Contacts

Public ContactDr Dipesh Sonawane

Lupin Ltd.

dipeshsonawane@lupin.com07071570717

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026